CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant*

Yuanxi Kang†, Zhiwei Wu‡, Terrence C. K. Lau§, Xiaofan Lu¶, Li Liu‡, Allen K. L. Cheung‡, Zhiwu Tan‡, Jenny Ng‡, Jiansuo Liang†, Haibo Wang†, Saikam Li†, Bojian Zheng‡, Ben Li†, Li Chen‡, and Zhiwei Chen†sup

From the †AIDS Institute, Department of Microbiology and Research Center for Infection and Immunity, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China, §Center for Public Health Research, School of Medicine, Nanjing University, Nanjing 210093, China, the ‡Department of Biology and Chemistry, City University of Hong Kong, Kowloon Tong, Kowloon, Hong Kong SAR, China, ¶Shanghai Targetdrug Co. Ltd, 500 Caobao Lu, Shanghai 20023, China, and the **HKU-AIDS Institute Shenzhen Research Laboratory, Shenzhen-Hong Kong Institute of Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen 518020, China

Received for publication, February 20, 2012, and in revised form, March 21, 2012. Published, JBC Papers in Press, March 23, 2012, DOI 10.1074/jbc.M112.354084

Background: Maraviroc-resistant HIV-1 posts challenges to CCR5 antagonist discovery.

Results: CCR5 antagonist TD-0680 employs a novel mechanism for subnanomolar potency against HIV-1 entry, cell-mediated infection, and a TAK-779/Maraviroc-resistant variant.

Conclusion: Distinct binding mode of TD-0680 accounts for its enhanced potency.

Significance: Our findings have implications for drug design and developing TD-0680 as an antiretroviral and/or as a microbicide against HIV-1.

Regardless of the route of transmission, R5-tropic HIV-1 predominates early in infection, rendering C-C chemokine receptor type 5 (CCR5) antagonists as attractive agents not only for antiretroviral therapy but also for prevention. Here, we report the specificity, potency, and underlying mechanism of action of a novel small molecule CCR5 antagonist, TD-0680. TD-0680 displayed the greatest potency against a diverse group of R5-tropic HIV-1 and SIV strains when compared with its prodrug, TD-0232, the Food and Drug Administration-approved CCR5 antagonist Maraviroc, and TAK-779, with EC50 values in the subnanomolar range (0.09–2.29 nM). Importantly, TD-0680 was equally potent at blocking envelope-mediated cell-cell fusion and cell-mediated viral transmission as well as the replication of a TAK-779/Maraviroc-resistant HIV-1 variant. Interestingly, TD-0232 and TD-0680 functioned differently despite binding to a similar transmembrane pocket of CCR5. Site-directed mutagenesis, drug combination, and antibody blocking assays identified a novel mechanism of action of TD-0680. In addition to binding to the transmembrane pocket, the unique exo configuration of this molecule protrudes and sterically blocks access to the extracellular loop 2 (ECL2) region of CCR5, thereby interrupting the interaction between virus and its co-receptor more effectively. This mechanism of action was supported by the observations of similar TD-0680 potency against CD4-dependent and -independent SIV strains and by molecular docking analysis using a CCR5 model. TD-0680, therefore, merits development as an anti-HIV-1 agent for therapeutic purposes and/or as a topical microbicide for the prevention of sexual transmission of R5-tropic HIV-1.

After sexual transmission, HIV-1 rapidly establishes persistent infection and latency, posing significant challenges for interventions aimed at achieving sterilizing protection and a therapeutic cure (1). An ideal way to contain the AIDS epidemic, therefore, is to prevent HIV-1 sexual transmission by blocking the virus at the entry stage.

CCR5 is one of the major chemokine receptors that serves as a co-receptor for most primary HIV-1 and SIV strains to enter permissive cells (2–4). Blockade of CCR5 is expected to be safe because human individuals and red-capped mangabeys with naturally occurring homozygous CCR5 Δ32 and Δ32 deletions, respectively, are apparently healthy (5, 6). Because these hosts are naturally resistant to R5-tropic HIV or SIV infections, targeting CCR5 to block HIV-1 infection has been explored as a preventive strategy. The importance of such strategy is further supported by the observation that sexually transmitted viruses are predominantly R5-tropic (7, 8). For these reasons, considerable efforts have been placed in developing CCR5 antagonists. Several are being tested in clinical trials (9, 10), with Maraviroc already approved by the United States Food and Drug Administration for the treatment of HIV-1-infected individuals who have failed other antiretroviral regimens.

Theabbreviations used are: CCR5, C-C chemokine receptor type 5; EC, effective concentration; TM, transmembrane; ECL, extracellular loop; Env, envelope; CXCR4, C-X-C chemokine receptor type 4; TDF, tenofovir; hu, human; rh, rhesus macaque; MFI, mean fluorescence intensity; Nt, N terminus; ICL, intracellular loop; RLU, relative light units; VSV-G, vesicular stomatitis virus glycoprotein; PBMC, peripheral blood mononuclear cells; SIV, simian immunodeficiency virus.
imens and harbor only R5-tropic HIV-1 (9, 11). For the prevention of HIV-1 sexual transmission, a CCR5 antagonist-based microbicide is an attractive agent that is being tested in preclinical studies (12). As proof-of-concept, a small molecule CCR5 antagonist CMPD 167, which prevents the interaction of HIV-1 envelope (Env) gp120 with its co-receptor CCR5, was able to completely block SHIV 162P4 vaginal transmission as a potential microbicide in a macaque model (13).

Because transmission of cell-associated HIV-1 can be several thousand-fold more efficient than cell-free virus (14), we aimed to search for a CCR5 antagonist with significantly improved potency not only in blocking infection with genetically divergent HIV-1 and SIV but also to prevent viral cell-to-cell transmission. In this study, we further examined the specificity, potency, and mechanism of action of two novel CCR5 antagonists, TD-0232 and its derivative TD-0680 (15–17). By investigating TD-0232 and TD-0680 in parallel with the CCR5 antagonists TAK-779 and Maraviroc, we showed that TD-0680 has the highest activity against entry and cell-mediated infection of diverse HIV-1 strains as well as a TAK-779/Maraviroc-resistant variant. Moreover, we uncovered a novel mechanism underlying the enhanced potency of TD-0680.

EXPERIMENTAL PROCEDURES

Materials—TD-0232 and TD-0680 were synthesized by Shanghai Targetdrug Co. Ltd, China. TD-0232 was designated as Compound 30 in Ma et al. (15) and nifeviroc in Ben et al. (16) and Li et al. (17), whereas TD-0680 was designated as Compound 26 in Li et al. (17). The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health (Germantown, MD); anti-CCR5 monoclonal antibodies 45502 and 45531; antiretrovirals azidothymidine, emtricitabine, tenofovir (TDF), efavirenz, nevirapine, raltegravir, TAK-779, Maraviroc and JM2987; cell lines TZM-bl, CEM×174 5.25 M7, CEM-NK–CCR5, and GHOST(3)-CD4 series. Plasmids encoding Env HIV-1ADA, HIV-1JR-FL, SIVmac239 and SIVmac1A11, Env plus Tat or co-transfected with plasmids encoding Env and the pHIV-1NL4–3R backbone, were maintained in culture medium for adherent cells supplemented with 10 units/ml recombinant human interleukin-2 (IL-2) (Roche Applied Science) and stimulated with 500 μg/ml puromycin, and 100 μg/ml hygromycin B (Invitrogen). CEM×174 5.25 M7 cells were maintained in culture medium for adherent cells supplemented with 500 μg/ml G418, 1 μg/ml puromycin, and 100 μg/ml hygromycin B. Fresh PBMCs were isolated from buffy coats of healthy donors (Hong Kong Red Cross, Hong Kong SAR, China) by gradient centrifugation using Lymphoprep (Axis-Shield PoC AS, Oslo, Norway). Total PBMCs were maintained in culture medium for non-adherent cells supplemented with 10 units/ml recombinant human interleukin-2 (IL-2) (Roche Applied Science) and stimulated with 5 μg/ml phytohemagglutinin (Sigma) for 3 days before use. Env-pseudotyped viruses were generated by co-transfecting 293T cells with plasmids encoding Env and the pHIV-1NL4–3R E–E–Luc or pSIVmac239R E–E–Luc+ luciferase reporter backbone.

Antiviral Assays—Two assays were performed as previously described (18). Briefly, (i) for single-cycle infectivity assays, GHOST(3)-CD4 cells were seeded into 96-well plates (1 × 10^5/ well) and preincubated in the presence or absence of compounds at 37 °C for 1 h before the addition of 5–30 μl of Env-pseudotyped luciferase reporter virus stock. At 48-h post-infection, cells were lysed, and luciferase activity of lysate was measured by using the Bright-Glo Luciferase Assay System (Promega, Madison, WI). (ii) For the PBMC assay, 2 × 10^5 phytohemagglutinin and IL-2-stimulated PBMCs were pretreated with or without compound for 1 h and infected by primary HIV-1 virus (0.01 multiplicity of infection) for 7–14 days. Viral replication was measured using a RETRO-TEK HIV-1 p24 Antigen ELISA kit (ZeptoMetrix, Buffalo, NY). Relative light units (RLU) revealing luciferase activity or p24 concentration were measured by Inspire VICTOR^® Multilabel Counter (PerkinElmer Life Sciences). Percentage of viral entry was calculated by (RLU with compound − RLU without virus)/(RLU without compound − RLU without virus) × 100%. Percentage of inhibition of viral infection was calculated as 100% − % viral entry. All experiments were performed in duplicate or triplicate and repeated at least twice. A nonlinear regression sigmoidal dose-response (variable slope) curve was adopted to determine the effective concentration (EC_{50}) value using the GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Env-mediated Cell-Cell Fusion Assay—(i) 293T cells were transfected with a plasmid encoding both R5-tropic Env and Tat or co-transfected with plasmids encoding Env and Tat individually. After 48 h of incubation, transfected 293T cells (donor) were detached with Enzyme-free PBS-based Cell Dissociation Buffer (Invitrogen). TZM-bl cells that express CD4 and CCR5 and contain a long terminal repeat-driven luciferase reporter gene that could be initiated by Tat protein (19) were preincubated with or without compound for 1 h and used as target cells. Donor and target cells were mixed in a 96-well plate at a 1:1 ratio. During Env-mediated cell-cell fusion, Tat was transferred from 293T cells to TZM-bl cells and induced the expression of luciferase. 18 h later, cells were lysed and assayed for luciferase activity. (ii) 293T cells were transfected with GFP-
tagged HIV-1JR-FL-expressing plasmid. 48 h later, supernatants were discarded, and 293T cells were washed with PBS twice. CEM X174 5.25 M7 cells were preincubated with or without compound for 1 h and used as target cells. Donor 293T cells were mixed with target cells at a 1:2 ratio. 18 h after co-culture, cells were washed with PBS twice. 106 CEM-NK cells were preincubated with 100 nM RANTES or CCR5 antagonist at 37 °C for 1 h before incubation with phycoerythrin-labeled or purified anti-CCR5 monoclonal antibody (mAb) at 4 °C for 1 h. Alexa Fluor 488-conjugated goat anti-mouse antibody was used as a secondary antibody against purified anti-CCR5 mAb. Data were acquired using FACSCalibur (BD Biosciences) and analyzed by Flowjo software (Tree Star, Ashland, OR). Percentage of mAb binding was calculated by using the formula (MFIinhibitor − MFIisotype)/(MFIdiluent − MFIisotype) × 100%. Inhibition of CCR5 antagonist on antibody binding was reflected by the reduction of percentage of mAb binding (100% − % mAb binding).

RESULTS

Anti-HIV-1 Specificity of CCR5 Antagonists TD-0232 and TD-0680—We previously reported that TD-0232 is an orally bio-available CCR5 antagonist with potency against R5-tropic HIV-1 infectivity at nanomolar concentrations (15). Structural optimization of TD-0232 by medicinal chemistry resulted in the subsequent synthesis of TD-0680 with four major modifications: (i) substitution of the carbamate linker with a urea linker, (ii) replacement of the nitro-moiety with a SO2N(CH3)2 group, (iii) the addition of a tropine bridge (exoisomer), and (iv) introduction of a fluoro group at the three-position of the phenyl ring (Fig. 1A) (16, 17).

To investigate the specificity of TD-0680, we first adopted a single-cycle infectivity assay using GHOST(3)-CD4-X4R5 as target cells (4, 26). HIV-1NL4-3 luciferase reporter viruses were pseudotyped with different Envs, including R5-tropic HIV-1ADA, X4-tropic HIV-1HxB2, and multi-tropic VSV-G. Before exposure to pseudovirions, cells were pretreated with 1 μM maraviroc, TD-0232, TD-0680, or JM2987 (a CXCR4 antagonist) (27). We found that similar to Maraviroc and TD-0232, TD-0680 inhibited R5-tropic HIV-1ADA but not X4-tropic HIV-1HxB2. Conversely, JM2987 blocked X4-tropic HIV-1HxB2 but not R5-tropic viruses. All four compounds failed to prevent HIV-1VSV-G infection (Fig. 1B, left). Next, we sought to determine whether TD-0232 and TD-0680 can block dual-tropic HIV-1R5X4 using GHOST(3)-CD4-CCR5 (Fig. 1B, middle) or GHOST(3)-CD4-CXCR4 (Fig. 1B, right) as target cells. Both cells were treated with PMA (1 μM) to activates T-cell receptor and control cell viability. All four compounds were able to block dual-tropic HIV-1R5X4 infection, possibly due to a weak endogenous expression of CXCR4 in GHOST(3)-CD4-CCR5 cells (28). These findings indicated that, like Maraviroc, TD-0232 and TD-0680 are specific HIV-1 entry inhibitors that function only by antagonizing CCR5 and not CXCR4, in line with previous findings that they could block the binding of the chemokine RANTES to CCR5 (15, 17).

TD-0680 Inhibits Diverse R5-tropic HIV-1 and SIV, Env-mediated Cell-Cell Fusion, and Cell-mediated Viral Transmission at Subnanomolar Concentrations—The antiviral potency of TD-0232 and TD-0680 was determined using several assays. First, TD-0232 and TD-0680 were tested in a single-cycle infectivity assay using GHOST(3)-CD4-CCR5 cells against a panel of genetically diverse R5-tropic HIV-1 and SIV Env-pseudotyped viruses, including primary Envs derived from six chronically
Novel Mechanism of C-C Chemokine Receptor Type 5 Antagonist TD-0680

infected Chinese patients (CNE, Chinese Env) (29). As summarized in Table 1, TD-0680 was found to be the most potent, with broad inhibitory activities against multiple HIV-1 subtypes. In these experiments the EC50 of TD-0680 ranged from 0.30 to 1.99 nM with a mean of 0.97 nM, which is significantly more potent than the other CCR5 antagonists (p < 0.01, Mann-Whitney test). Interestingly, TD-0680 was also effective against both neutralization-resistant SIVmac239 (EC50 = 2.29 nM) and CD4-independent neutralization-sensitive SIVmac1A11 (EC50 = 1.43 nM), likely due to similar CCR5 usage between HIV-1 and SIV as we previously described (4). Second, we determined the EC50 values of TD-0232 and TD-0680 against primary HIV-1 isolates in PBMC assays and compared them with TAK-779 or Maraviroc (30). Only TD-0680 displayed subnanomolar EC50 values against three genetically divergent R5-tropic HIV-1 clinical isolates: 10HK1661 (clade B), 10HK1447 (clade CRF01_AE), and 93IN109 (clade C) (Fig. 2A). Third, taking into consideration the enhanced transmissibility of cell-associated HIV-1 (14), we sought to determine whether TD-0680 could block the virus in an Env-mediated cell-cell fusion and cell-mediated viral transmission model (31). Consistently, TD-0680 exhibited potent inhibitory activity at subnanomolar levels against cell-cell fusion mediated by R5-tropic Envs of three major genotypes, whereas TAK-779, TD-0232, and Maraviroc displayed a reduced efficacy (Fig. 2B). As expected, reverse transcriptase inhibitor TDF did not show any inhibitory activity against cell-cell fusion.

![Chemical structures of TD-0232 and TD-0680](image1)

**TABLE 1**

Antiviral activities of small molecule CCR5 antagonists using a single-cycle infectivity assay

| Env-pseudotyped virus | Clade | EC50 ± S.D. |
|-----------------------|-------|------------|
| HIV-1ADA              | B     | 29.07 ± 15.08 2.72 ± 0.21 1.00 ± 0.69 0.30 ± 0.17 |
| HIV-1JR-FL            | B     | 88.71 ± 58.89 3.28 ± 0.62 6.85 ± 2.74 1.01 ± 0.28 |
| HIV-1CNE6             | B'    | 53.69 ± 28.55 3.55 ± 0.33 3.36 ± 2.86 0.93 ± 0.31 |
| HIV-1CNE11            | B'    | 203.60 ± 37.34 9.54 ± 3.37 14.09 ± 2.98 1.99 ± 1.28 |
| HIV-1CNE13            | B' C  | 35.74 ± 29.59 3.22 ± 1.71 6.75 ± 7.18 1.35 ± 1.46 |
| HIV-1CNE30            | CRF08_BC | 14.99 ± 7.88 2.19 ± 0.54 2.08 ± 0.47 0.67 ± 0.33 |
| HIV-1CNE31            | CRF01_AE | 35.49 ± 4.91 4.22 ± 2.09 2.98 ± 1.15 0.87 ± 0.53 |
| HIV-1CNE35            | CRF01_AE | 33.53 ± 13.06 2.44 ± 0.88 2.47 ± 2.24 0.61 ± 0.52 |
| Mean                  |       | 61.85 ± 3.90 4.95 ± 0.97 |
| SIVmac239             |       | 95.45 ± 29.49 8.21 ± 0.86 14.45 ± 0.93 2.29 ± 0.66 |
| SIVmac1A11            |       | 14.09 ± 2.48 1.38 ± 0.10 4.58 ± 1.54 1.43 ± 0.29 |
| Mean                  |       | 54.77 ± 4.80 9.52 ± 1.86 |

FIGURE 1. TD-0680 is a novel CCR5 antagonist. A, shown are the chemical structures of TD-0232 (M, 590.71, left) and TD-0680 (M, 695.89, right). B, TD-0680 selectively inhibits HIV-1 infection through CCR5 co-receptor. GHOST(3)-CD4-X4R5 (left), GHOST(3)-CD4-CCR5 (middle), or GHOST(3)-CD4-CXCR4 (right) cells were infected with indicated Env-pseudotyped HIV-1 luciferase reporter viruses. All viral entry experiments were conducted in the presence or absence of 1 μM JM2987, Maraviroc, TD-0232, or TD-0680. Each group was tested in triplicate, and data are presented as the mean ± S.D.
in this model (32). Furthermore, we co-cultured GFP-tagged live HIV-1JR-FL-producing 293T cells with CEM/174 M7 cells in the presence or absence of various serially diluted inhibitors. As shown in Fig. 2C, although micromolar amounts of TDF and TAK-779 were required to achieve 100% inhibition of syncytia formation, the EC100 of TD-0680 was 4 nM, 4-fold lower than that required for TD-0232 and Maraviroc. Thus, TD-0680 not only exhibits increased potency against cell-free virus as compared with other CCR5 antagonists but may also offer a major advantage in the prevention of cell-to-cell spread of HIV-1.

**TD-0680 Inhibits TAK-779/Maraviroc-resistant HIV-1 Variant**—It has been previously reported that R5-tropic HIV-1JR-FL, producing 293T cells with CEM×174.5.25 M7 cells in the presence or absence of various serially diluted inhibitors. As shown in Fig. 2C, although micromolar amounts of TDF and TAK-779 were required to achieve 100% inhibition of syncytia formation, the EC100 of TD-0680 was 4 nM, 4-fold lower than that required for TD-0232 and Maraviroc. Thus, TD-0680 not only exhibits increased potency against cell-free virus as compared with other CCR5 antagonists but may also offer a major advantage in the prevention of cell-to-cell spread of HIV-1.

**TD-0680 Inhibits TAK-779/Maraviroc-resistant HIV-1 Variant**—It has been previously reported that R5-tropic HIV-1JR-FL, producing 293T cells with CEM×174.5.25 M7 cells in the presence or absence of various serially diluted inhibitors. As shown in Fig. 2C, although micromolar amounts of TDF and TAK-779 were required to achieve 100% inhibition of syncytia formation, the EC100 of TD-0680 was 4 nM, 4-fold lower than that required for TD-0232 and Maraviroc. Thus, TD-0680 not only exhibits increased potency against cell-free virus as compared with other CCR5 antagonists but may also offer a major advantage in the prevention of cell-to-cell spread of HIV-1.

**TD-0680 Uses Distinct Binding Motif to Human and Rhesus CCR5**—To evaluate the potential of TD-0680 for clinical development, we performed viral inhibitory assays using a combina-
tion with several classes of antiretroviral compounds including nucleoside reverse transcriptase inhibitors azidothymidine, emtricitabine and TDF, nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine, and integrase inhibitor raltegravir (20). As expected, TD-0680 displayed no antagonistic effects when combined with any of these antiretrovirals, suggesting a possible application in mixture therapy (Table 2).

TD-0680, however, had strong antagonism with TD-0232 and moderate antagonism with Maraviroc, likely due to targeting of a common region in CCR5 by these drugs.

To further define the binding motif on CCR5 of TD-0680, a panel of single-residue mutants of human CCR5 (huCCR5) was generated spanning the N terminus (Nt), intracellular loop 2, ECL2, and TM domains (Fig. 4). GHOST(3)-CD4-CCR1 cells, which do not support HIV-1 infection, were transfected with each of the huCCR5 mutants followed by treatment with a fixed concentration of CCR5 antagonist and subsequent infection with an R5-tropic HIV-1CNE3. In accordance with previous studies, a 14% viral entry was used as the cut-off level, above which a CCR5 mutant is considered insensitive to the respective antagonist (21, 22). Individual amino acid substitutions tested in the ECL2 of CCR5 seemed to have little effects on the activity of all three CCR5 antagonists tested. Amino acid residues previously reported to be critical for the inhibitory activity of Maraviroc (e.g. Trp-86 in TM2, Tyr-108 in TM3, Ile-198 in TM5, Tyr-251 in TM6, and Glu-283 in TM7) were confirmed in this assay, validating its utility (Fig. 4A) (34, 35). Interestingly, these residues also significantly affected TD-0232 activity, indicating that Maraviroc and TD-0232 use an overlapping binding domain within the CCR5 TM pocket. Surprisingly, TD-0680 was affected by W86A in TM2, I198A in TM5, and E283A in TM7 but not by Y108A in TM3, I198M in TM5, or Y251A in TM6, postulating that TD-0680 uses a binding domain that differs from TD-0232 and Maraviroc.

HuCCR5 and its rhesus macaque homolog (rhCCR5) had been reported to exhibit differential sensitivity to CCR5 antagonists such as SCH-C and CMPD 167 (13, 22). Thus, we focused on the impact of eight human-to-rhesus CCR5 mutants on the efficacy of TD-0232 and TD-0680 against HIV-1CNE3 infection. We found that the I198M mutation in TM5 reduced the anti-

TABLE 2  
Anti-HIV-1 effect of TD-0680 in combination with different classes of antiretroviral agent

| Antiretroviral agent | Synergy vol/antagonism vol\(^a\) | Combined effect\(^b\) |
|----------------------|-------------------------------|----------------------|
| Nucleoside reverse transcriptase inhibitor | | |
| Azidothymidine | 0.23/−14.05 | Additive |
| Emtricitabine | 0.67/−10.79 | Additive |
| TDF | 12.80/−11.13 | Additive |
| Nonnucleoside reverse transcriptase inhibitor | | |
| Efavirenz | 0.51/−3.2 | Additive |
| Nevirapine | 0/−2.14 | Additive |
| Integrase inhibitor | | |
| Raltegravir | 0.48/−0.28 | Additive |
| CCR5 neutralization antibody | | |
| 2D7 | 0.78/−39.43 | Additive |
| CCR5 antagonist | | |
| Maraviroc | 0/−83.03 | Antagonistic |
| TD-0232 | 0/−117.19 | Antagonistic |

\(^a\) Volumes of synergy and antagonism (nM\(^2\)%) were calculated at 95% confidence intervals using data from at least two independent assays.

\(^b\) Synergy (assigned a positive value) or antagonism (assigned a negative value) was defined as drug combinations yielding mean volumes in excess of 50 nM\(^2\)%, and additive drug interactions were defined by mean volumes of 0 to 50 nM\(^2\)%.
The tropane bridge of TD-0680 was stabilized by the hydrophobicity of Trp-86, Leu-104, and Thr-105, and the fluorophenyl ring of TD-0680 was sandwiched between indole group of Trp-86, Leu-104, and Thr-105, and the fluorophenyl group of Tyr-89. Thr-177, Cys-178, and Ser-179, which locate at ECL2, interacted and stabilized the pyrrolidine core of TD-0680 possibly through hydrophobic interactions. In contrast, the *endo* isomer of TD-0680, which also binds the same TM pocket, exhibited no ECL2 blockade similar to TD-0232 (Fig. 5D).

To further determine the mechanism of ECL2 blockade, we investigated the influence of TD-0680 on the binding of mAb to CCR5 extracellular domains Nt and ECL2, which are essential for HIV-1 entry (39–41). 45502, CTC8, 2D7, and 45531 are mouse anti-human CCR5 mAbs targeting the first half of Nt (Nt-A), the second half of Nt (Nt-B), the first half of ECL2 (ECL2-A), and the second half of ECL2 (ECL2-B), respectively (40). Their binding affinities to CCR5-expressing leukemic lymphoid CEM-NK6 cells (CEM-NK6-CCR5) were determined by measuring the MFI using flow cytometry in the presence of 100 nM CCR5 antagonists as previously described (41). β-Chemokine RANTES, a natural ligand of CCR5, was included as a positive control. Indeed, RANTES significantly affected the binding of all anti-CCR5 mAbs by inducing CCR5 internalization, whereas CCR5 antagonists did not show similar effects (Fig. 6) (42). None of the CCR5 antagonists affected the Nt-A and Nt-B binding of 45502 and CTC8, respectively, suggesting that their inhibitory activities were unlikely Nt-dependent. The ECL2-B binding of 45531, however, was reduced by all four CCR5 antagonists, with TD-0680 showing the most significant loss (80.2% reduction). Moreover, the ECL2-A binding of 2D7 was also most significantly blocked by TD-0680 (51.7% reduction). Overall, these results demonstrated that due to its unique structure, TD-0680 exerts its function by interfering with both the ECL2-A and ECL2-B regions of CCR5.
DISCUSSION

In this study we report the anti-HIV-1 specificity, potency, and mechanism of action of two novel small molecule CCR5 antagonists, TD-0232 and TD-0680. We demonstrated that both TD-0232 and TD-0680 inhibited HIV-1 entry by specifically blocking virus interaction with the CCR5 co-receptor (Fig. 1). Compared with TAK-779, Maraviroc, and TD-0232, TD-0680 showed the highest anti-HIV-1 activity against a panel of genetically divergent R5-tropic HIV-1 (clades B, B'/H11032, B'/H11032 C, CRF08_BC, and CRF01_AE) and SIVmac strains in both pseudoviral (Table 1) and PBMC assays (Figs. 2 and 3), with EC_{50} values in the subnanomolar range (0.09–2.29 nM). The EC_{50} values of TD-0680 were consistently 2–28-fold better than TD-0232 or Maraviroc, whereas the 50% cytotoxic concentrations (CC_{50}) of TD-0680 and TD-0232 were comparable (113 versus 98 μM) in Vero cells in our experiments. Moreover, TD-0680 was able to block Env-mediated cell-cell fusion and cell-mediated viral transmission as well as infection of PBMCs with a TAK-779/Maraviroc-resistant HIV-1 variant at the same subnanomolar concentrations (Figs. 2, B and C, and 3). These features together with the lack of antagonistic effects with commonly used antiretrovirals (Table 2) and a significantly improved selectivity index and reduction of 50% hERG (human ether-a-go-go related gene) affinity as compared with TD-0232 (16, 17), render TD-0680 an attractive drug candidate for AIDS treatment and prevention.

TD-0680 showed antagonistic effects with Maraviroc and TD-0232 in drug combination assays (Table 2), suggesting that it functions by binding into the TM pocket of CCR5. Indeed, the antiviral activity of TD-0680 remained sensitive to some amino acid changes (e.g. W86A, I198A, and E283A) located within the pocket (Fig. 4A). However, several lines of evidence indicated that TD-0680 employed a binding motif that is distinct from TD-0232 and other CCR5 antagonists. First, besides improved antiviral potency as discussed above, TD-0680 remained effective against a human-to-rhesus CCR5 mutant I198M that was previously found to be the cause for the insensitivity of rhCCR5 to SCH-C (22), explaining its potency in blocking HIV/SIV infections into rhCCR5-expressing cells (Fig. 4). Second, mutagenesis study showed that TD-0680 was either insensitive

FIGURE 5. Binding mode of TD-0232 and TD-0680 to CCR5. Molecular docking of TAK-779 (A), Maraviroc (B), TD-0232 (C), and color-coded TD-0680 and its endo isomer (D) are shown with the CCR5 model. The structure of CCR5 is shown in ribbon format. Molecules are shown in Corey-Pauling-Koltun format with indicated coloring: carbon (gray), oxygen (red), and fluoro (light blue). The ECL2 region is indicated. The figure is generated using Discovery studio visualizer (Accelrys, San Diego, CA). Detailed interaction of TD-0232 (E) and TD-0680 (F) with CCR5 model in a stereo view is presented. The interacting residues are highlighted in the figure with the same coloring scheme as described.
or was less dependent on amino acids such as Tyr-108 in TM3 and Tyr-251 in TM6 within the pocket (Fig. 4A). Docking analysis suggested that the loss of hydrophobicity due to Y108A or Y251A mutations was likely compensated by the extensively interactions of TD-0680 to CCR5, which was extended from the deep hydrophobic TM pocket to the ECL2 region. Last, TD-0680 was effective against both wild-type HIV-1_Bal.c2.2wt and the TAK-779/Maraviroc-resistant HIV-1_Bal.c5.6r strains at subnanomolar concentrations, with a less than 5-fold change in IC_{50} values as compared with the >40-fold (e.g. TD-0232 and Maraviroc) and 100-fold changes (e.g. TAK-779) for the other CCR5 antagonists (Fig. 3). Taken together, these findings suggested that TD-0680 acts upon CCR5 through an overlapping yet distinct mechanism from TD-0232 or Maraviroc.

The unique mechanism of action of TD-0680 is closely linked to its exo configuration. Molecular docking analysis using CXCR4 as a template revealed that this rigid exo configuration formed a unique physical protruding obstacle from the ECL2 of CCR5 (Fig. 5, D and F), a region that is required to interact with the V3 loop of gp120 in viral entry (43). This mechanism of action is further supported by the observation that analogs of TD-0680 with an endo configuration displayed significantly reduced anti-HIV-1 activity despite comparable CCR5 binding affinity (17). Moreover, in line with this inhibitory mechanism, antibody-blocking data showed that TD-0680 affected mAb 45531 binding to ECL2-B as well as the binding of mAb 2D7 to ECL2-A (Fig. 6), the latter being a potent neutralizing antibody against R5-tropic HIV-1 infection (40). As the affinity of TD-0680 to CCR5 was actually lower than that of Maraviroc, with an IC_{50} of 11.4 nM versus 5.2 nM in inhibition of RANTES-induced GTP binding assay (11, 17), the enhanced potency of TD-0680 may simply be a function of its extensive physical protrusion after binding to CCR5 to block both the ECL2-B and ECL2-A regions more effectively. This mechanism may explain the superior activity of TD-0680 against the TAK-779/Maraviroc-resistant HIV-1_Bal.c5.6r strain, which is a competitive resistant virus and may use a different yet ECL2-dependent conformation for entry (44). Besides the physical barrier, it is possible that the inhibitory mechanism of TD-0680 also involves a bigger conformational change in the ECL2 of CCR5 that is no longer recognizable by HIV-1 through an allosteric binding to the transmembrane domains (22, 41, 45). These novel findings have important implications for drug design. However, because the identity of TMs between CCR5 and CXCR4 is about 35.4% (35), our CCR5 model is approximate, and molecular docking of inhibitors is mainly tentative. Our hypothetical mechanism remains to be confirmed by future structural and functional analysis.

TD-0680 can be a salvage choice for patients who have developed a competitive resistant virus like HIV-1_Bal.c5.6r (46, 47). Although rare, treatment failure has been documented due to Maraviroc-resistant R5-tropic-remaining viruses detected in Maraviroc-treated patients (45). It should be mentioned that despite rigorous efforts, we have not been able to obtain a TD-0680-resistant virus even though non-nucleoside reverse transcriptase inhibitor F18-resistant viruses were readily generated in our laboratory (18). Given the steep slopes of TD-0680 inhibition kinetics (Figs. 2, A and B, and 3D), this failure might be related to the difficulty of capturing a suboptimal drug condition for resistant viruses to emerge, resulting in a high resistance barrier. Continuing efforts will be given to address this issue in future studies. Schanzer et al. (48) recently demonstrated that a bi-specific CCR5 antibody displays potent neutralizing activity against resistant viruses by targeting both the Nt and ECL2. Our future studies should investigate the potency of TD-0680 on other R5-tropic non-competitive CCR5 antagonist-resistant viruses, which might be more dependent on the Nt of CCR5 for entry (41, 45).

TD-0680 is >1000-fold better than TDF in blocking cell-mediated HIV-1 transmission. A recent landmark work by Abdool Karim et al. (49) demonstrated that a TDF microbicide gel used by women before sex reduced their risk of HIV infection by 39%. Although TDF blocks cell-free virus effectively, it failed to completely inhibit HIV-1 cell-to-cell spread (32), a much more efficient mode of virus transmission (14). In this regard we also demonstrated that TDF was unable to block HIV-1 Env-mediated cell-cell fusion or cell-mediated viral

---

**FIGURE 6. Inhibition of mAb binding by CCR5 antagonists.** A, representative results of mAb binding are shown. mAb binding affinity was revealed by flow cytometry. B, statistics of antibody binding are shown. Data represent the mean ± S.D. from two to six independent experiments. For clarity, mean values >100% (not significant) are plotted as 100%. Two-tailed Student’s t test was used for group comparison. *, p < 0.05; **, p < 0.01; ns, not significant.
transmission up to 10 μM concentration, which contrasted with the single-digit 4 nM EC_{100} achieved by TD-0680 (Fig. 2C), a >1000-fold difference. Conceivably, TD-0680 will be an excellent microbicidal candidate for preventing HIV-1 sexual transmission. To this end, unlike Maraviroc, TD-0680 blocked both huCCR5 and rhCCR5 almost equally well (Fig. 4). This property will greatly facilitate a TD-0680-based drug or microbicidal gel to be tested for safety and efficacy evaluation in SHIV/macaque models.

Acknowledgments—We sincerely thank Jose Esté for providing CCR5 antagonist-resistant viruses, Jingjing Li for contributing CNE envelopes, Wenbo Yu and Faye Cheung for helpful discussions, Xian Tang, and Jingling Li for technical assistance.

REFERENCES

1. Geeraert, L., Kraus, G., and Pomerantz, R. J. (2008) Hide and seek. The challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 59, 487–501

2. Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Luzio, P. (1995) Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811–1815

3. Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhardt, M., Di Marzio, P., Marmon, S., Schall, T. J., Littman, D. R., and Landau, N. R. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661–666

4. Chen, Z., Zhou, P., Ho, D. D., Landau, N. R., and Marx, P. A. (1997) Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J. Virol. 71, 2705–2714

5. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Gallo, R. C., and Marx, P. A. (1998) Natural infection of a homozygous A residues CCR5 in macaques to treat simian immunodeficiency virus infection kinetics. J. Virol. 62, 2182–2190

Price, D., Stammen, B., Wood, A., and Perros, M. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732

12. Neff, C. P., Kurisu, T., Ndolo, T., Fox, K., and Akkina, R. (2011) A topical microbicidal gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 6, e2009

13. Veazey, R. S., Klasse, P. J., Ketas, T. I., Reeves, J. D., Piatak, M., Jr., Kunstman, K., Kuhmann, S. E., Marx, P. A., Liison, J. D., Dufour, J., Mefford, M., Pandrea, I., Wolinsky, S. M., Doms, R. W., DeMartino, J. A., Siciliano, S. J., Lyons, K., Springer, M. S., and Moore, J. P. (2003) Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198, 1551–1562

14. Dimitrov, D. S., Willey, R. L., Sato, H., Chang, L. J., Blumenthal, R., and Martin, M. A. (1993) Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67, 5639–5644

15. Ma, D., Yu, S., Li, B., Chen, L., Ren, Y., Zhang, L., Chen, Z., Zhong, D., Gong, Z., Wang, R., Jiang, H., and Pei, G. (2007) Synthesis and biological evaluation of 1,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ChemMedChem 2, 175–193

16. Ben, L., Jones, E. D., Zhou, E., Li, C., Baylis, D. C., Yu, S., Wang, M., He, X., Coates, J. A., Rhodes, D. I., Pei, G., Deadman, J. J., Xie, X., and Ma, D. (2010) Studies on the structure-activity relationship of 1,3,4,5-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents. Bioorg. Med. Chem. Lett. 20, 4012–4014

17. Li, B., Jones, E. D., Zhou, E., Chen, L., Baylis, D. C., Yu, S., Wang, M., He, X., Coates, J. A., Rhodes, D. I., Pei, G., Deadman, J. J., Xie, X., and Ma, D. (2010) Studies on the structure-activity relationship of 1,3,4,5-tetra-substituted pyrrolidine-embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents. Bioorg. Med. Chem. Lett. 20, 5334–5336

18. Lu, X., Liu, L., Zhang, X., Liu, T. C., Tsui, S. K., Kang, Y., Zheng, P., Zheng, B., Liu, G., and Chen, Z. (2012) F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Antimicrob. Agents Chemother. 56, 341–351

19. Wei, X., Deckter, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J., M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896–1905

20. Prichard, M. N., and Shipman, C., Jr. (1990) A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14, 181–205

21. Dragic, T., Trkola, A., Thompson, D. A., Cormier, E. G., Kajumo, F. A., Dragic, T., Trkola, A., Thompson, D. A., Cormier, E. G., Kajumo, F. A., and Hahn, B. H. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U.S.A. 97, 5639–5644

22. Billic, E., Seibert, C., Pugach, P., Ketas, T., Trkola, A., Endres, M. J., Murgo, N. J., Coates, E., Reyes, G. R., Baroudy, B. M., Sakmar, T. P., and Moore, J. P. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Nature 401, 413–414

23. Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006) The SWISS-MODEL workspace. A web-based environment for protein structure homology modeling. Bioinformatics 22, 195–201

24. Morris, G. M., Goodsell, D. S., Hallday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639–1662

25. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., and Olson, A. J. (2009) AutoDock4 and AutoDockTools4. Automated docking with selective receptor flexibility. J. Comput. Chem. 30,
Novel Mechanism of C-C Chemokine Receptor Type 5 Antagonist TD-0680

2785–2791
Wu, H., Zhuang, K., Liu, L., Tang, Z., Tang, J., Tien, P., Zhang, L., and Chen, Z. (2010) Acute infection of Chinese macaques by a CCR5-tropic SHIV carrying a primary HIV-1 subtype B’ envelope. J. Acquir. Immune Defic. Syndr. 53, 285–291

2786
De Clercq, E., Yamamoto, N., Pauwels, R., Balzarini, J., Witvrouw, M., De Vreeze, K., Debyser, Z., Rosenwirth, B., Peichl, P., and Datema, R. (1994) Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38, 668–674

2787
Mörner, A., Bjørndal, A., Albert, J., Kewalramani, V. N., Littman, D. R., Inoue, R., Thorstensson, R., Fenyö, E. M., and Björling, E. (1999) Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73, 2343–2349

2788
Shang, H., Han, X., Shi, X., Zuo, T., Goldin, M., Chen, D., Han, B., Sun, W., Wu, H., Wang, X., and Zhang, L. (2011) Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J. Biol. Chem. 286, 14531–14541

2789
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiroma, I., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K., and Fujino, M. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96, 5698–5703

2790
Garg, H., Joshi, A., Freed, E. O., and Blumenthal, R. (2007) Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J. Biol. Chem. 282, 16899–16906

2791
Sigal, A., Kim, J. T., Balazs, A. B., Dekel, E., Mayo, A., and Baltimore, D. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95–98

2792
Armand-Ugón, M., Moncunill, G., Gonzalez, E., Mena, M., Ballana, E., Clotet, B., and Esté, J. A. (2010) Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. J. Antimicrob Chemother 65, 417–424

2793
Kondru, R., Zhang, J., Ji, C., Mirzadegan, T., Rotstein, D., Sankuratri, S., and D'Angioz, M. (2008) Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73, 789–800

2794
García-Perey, J., Rueda, P., Alcami, J., Rognan, D., Arenzana-Seisdedos, F., Lagane, B., and Kellenberger, E. (2011) Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J. Biol. Chem. 286, 33409–33421

2795
Xiao, X., Wu, L., Stantchev, T. S., Feng, Y. R., Ugolini, S., Chen, H., Shen, Z., Riley, J. L., Broder, C. C., Sattentau, Q. J., and Dimitrov, D. S. (1999) Constitutive cell surface association between CD4 and CCR5. Proc. Natl. Acad. Sci. U.S.A. 96, 7496–7501

2796
Achour, L., Scott, M. G., Shirvani, H., Thuret, A., Bismuth, G., Labbé-Jullié, C., and Marullo, S. (2009) CD4-CCR5 interaction in intracellular compartments contributes to receptor expression at the cell surface. Blood 113, 1938–1947

2797
Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, V., and Stevens, R. C. (2010) Structures of the CXCR4 chemo-kine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066–1071

2798
Huang, C. C., Lam, S. N., Acharya, P., Tang, M., Xiang, S. H., Hussan, S. S., Stanfield, R. L., Robinson, J., Sodroski, J., Wilson, I. A., Wyatt, R., Bewley, C. A., and Kwong, P. D. (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317, 1930–1934

2799
Lee, B., Sharron, M., Blanpain, C., Doranz, B. J., Vakili, J., Setoh, P., Berg, E., Liu, G., Guy, H. R., Durell, S. R., Parmentier, M., Chang, C. N., Price, K., Tsang, M., and Doms, R. W. (1999) Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274, 9617–9626

2800
Tsamis, F., Gavrilov, S., Kamano, S., Seibert, C., Kuhmann, S., Ketas, T., Tkola, A., Palani, A., Clader, J. W., Tagat, J. R., McCombie, S., Barouky, B., Moore, J. P., Sakmar, T. P., and Dragic, T. (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77, 5201–5208

2801
Mack, M., Luckow, B., Nelson, P. J., Cihak, J., Simmons, G., Clapham, P. R., Sigoret, N., Marsh, M., Stangasser, M., Borlat, F., Wells, T. N., Schlindorff, D., and Proudfoot, A. E. (1998) Aminoxyxypentane-RANTES induces CCR5 internalization but inhibits recycling. A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187, 1215–1224

2802
Cormier, E. G., and Dragic, T. (2002) The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76, 8953–8957

2803
Berro, R., Klasse, P. J., Lascano, D., Wiegler, A., Nagashima, K. A., Sanders, R. W., Sakmar, T. P., Hope, T. J., and Moore, J. P. (2011) Multiple CCR5 conformations on the cell surface are used differently by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J. Virol. 85, 8227–8240

2804
Tilton, J. C., Wilen, C. B., Didigui, C. A., Sinha, R., Harrison, J. E., Agrawal-Ganse, C., Henning, E. A., Bushman, F. D., Martin, J. N., Deeks, S. G., and Doms, R. W. (2010) A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84, 10863–10876

2805
Nozza, S., Galli, L., Visco, F., Soria, A., Canducci, F., Salpietro, S., Gianotti, N., Bigoni, A., Torre, L. D., Tambussi, G., Lazzarin, A., and Castagna, A. (2010) Raltegravir, maraviroc, etravirine. An effective protease inhibitor and nucleoside reverse transcriptase inhibitor–sparing regimen for salvage therapy in HIV–infected patients with triple-class experience. Aids 24, 924–928

2806
Parra, J., Portilla, J., Pulido, F., Sánchez-de la Rosa, R., Alonso-Villaverde, C., Berenguer, J., Blanco, J. L., Domingo, P., Dronda, F., Galera, C., Gutiérrez, F., Kindelán, J. M., Knobel, H., Leal, M., López-Aldeguer, J., Mariño, A., Miralles, C., Moltó, J., Ortega, E., and Oteo, J. A. (2011) Clinical utility of maraviroc. Clin. Drug Invest 31, 527–542

2807
Schanzer, J., Jekle, A., Nezu, I., Lochner, A., Crossdale, R., D'Angioz, M., Zhang, J., Hoffmann, E., Dormeyer, W., Stracke, J., Schäfer, W., Ji, C., Heilek, C., Cammack, M., Brandt, M., Umana, P., and Brinkmann, U. (2011) Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody–resistant HIV-1 strains. Antimicrob. Agents Chemother. 55, 2369–2378

2808
Abdool Karim, Q., Abdool Karim, S. S., Grobler, A. C., Stott, D., Hoosen, A. A., Hargreaves, J. H., Abdool Karim, S. S., Grobler, A. C., Adams, J., and Abdool Karim, S. S. (2011) Impact of introducing triple ART on HIV incidence in rural South Africa. PLoS Med. 8, e1001042